Accelerating patient recruitment in clinical trials post COVID-19

Artificial intelligence is changing how pharmaceutical companies operate, how they develop and study new treatments, and even what form those treatments take. Pharma companies are now pairing medicines with software — so-called digiceuticals powered by virtual reality and AI. Most of the world’s largest drug companies now have a technology officer in their C-suites. And AI is now being used to help find new drug targets, model diseases, and make clinical trials more efficient.

Insights from Patient Flows and Patient Journeys are cornerstones to the success of any pharma/medtech product. If the process of insight generation is well done, you will discover more impactful growth

Pharmaceutical Investigations and Technology (PIT) is a group within Global Analytical Technology (GAT) department in the commercial Quality organization within Bristol-Myers Squibb. The PIT group has been a key part in BMS for 30 + years in providing analytical support for commercial manufacturing and in pharmaceutical forensics. This include particulate and foreign matter characterization in pharmaceutical products and screening counterfeit drugs. Several analytical tools and techniques are used by PIT to support the pharmaceutical forensics.

The field of immuno-oncology has exploded in the clinic, in the press, and on Wall Street, particularly regarding the use of genetically modified immune cells to fight cancer. This “explosion” is largely due to the success of chimeric antigen receptor (CAR) T-cell therapy. The fields of immunology and gene therapy have converged to harness recombinant viruses to deliver “living drugs” with remarkable clinical efficacy, especially for patients with blood cancers. Multiple approaches to engineering immune cells mostly T cells but also other immune cell types make use of CARs, while tumor-specific T-cell receptors continue to gain a foothold in the field, mostly for the treatment of solid tumors. Several genome-editing approaches are now available, including established technologies such as zinc-finger nucleases, and newer modalities like the CRISPR/Cas9 system. These methodologies have recently been applied to augment the antitumor efficacy of adoptively transferred cells in the clinic by knocking out negative regulatory molecules such as PD1.